Actively Recruiting
Clinical Phenotypes, Risk Factors, and Outcomes in Functional Mitral and Tricuspid Valve Regurgitation in Atrial Fibrillation
Led by Barts & The London NHS Trust · Updated on 2026-04-21
141
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to better understand atrial valve disease by identifying clinical types and evaluating the risk factors and outcomes of functional mitral and tricuspid valve regurgitation in patients with atrial fibrillation. It focuses on examining differences between atrial mitral and tricuspid valve problems and their natural progression. The study is observational and designed to characterize these valve diseases and their impacts. Participants will be grouped into three categories: atrial functional mitral regurgitation (MR), atrial functional tricuspid regurgitation (TR), and mixed MR and TR. They will undergo several evaluations including baseline echocardiography, cardiopulmonary exercise (Cpex) echocardiography, blood tests measuring BNP, and follow-up echocardiography at one year. The study will observe and compare these subgroups over time. Throughout the study, participants will have heart ultrasounds and blood tests to assess valve function and heart health. Researchers will measure outcomes such as the effective regurgitant orifice area after one year, disease progression, functional status including New York Heart Association class and predicted VO2max, hospital admissions for heart failure, and mortality. The total follow-up is one year, with detailed monitoring to identify how valve disease changes and affects patients over time.
CONDITIONS
Brief Title
Atrial Functional Mitral Regurgitation and Tricuspid Regurgitation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Informed consent
- Age of 18 years or older
- Diagnosis of atrial fibrillation
- Moderate or severe atrial valve disease
- Adequate 2D echocardiography views including parasternal long axis, short axis, apical two chamber, apical three chamber and four chamber
You will not qualify if you...
- Unwilling or unable to give consent
- Left ventricular impairment with ejection fraction below 50%
- Primary or organic valve disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year
Participants undergo echocardiogram ultrasounds to assess heart valve function and classify valve disease.
Visits may occur during outpatient clinic or echocardiography laboratory appointments over 1 year
Duration - 1 year
Participants are monitored for progression of valve disease, heart function, hospital admissions, and mortality over one year.
Follow-up visits over 1 year to assess disease progression and health outcomes
Trial Site Locations
Total: 1 location
1
St Bartholomew's Hospital
London, United Kingdom
Actively Recruiting
Research Team
J
Jawza Aldakhil
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here